Latest Immutep News & Updates

See the latest news and media coverage for Immutep. We track all announcements, press releases, and industry mentions in real time, all in one place.

Immutep

Biotechnology company developing LAG-3 immunotherapies

immutep.com

Headquarters: Sydney, Australia
Company type: Public company
Number of employees: 10–60
Industry: Pharmaceuticals

Last updated Today

Latest news about Immutep

In short: Immutep advanced its clinical pipeline and intellectual property but faced a setback with the discontinuation of its TACTI-004 Phase III trial.

Company announcements

July 30 Immutep

Immutep releases Q4 FY26 quarterly activities report

Efti trials show 7.7-month OS benefit, IMP761 Phase I positive, TACTI-004 futility analysis ongoing, cash at A$68.87M.

July 14 Immutep

Immutep secures fourth US patent for eftilagimod alfa combination

The patent covers methods for treating cancer using efti with PD-1 pathway inhibitors, expanding IP protection until 2036.

July 13 Immutep

Immutep reports positive mature overall survival data from INSIGHT-003

Mature mOS of 30.9 months in 1L non-squamous NSCLC patients, including those with TPS<50%. TACTI-004 update with root cause analysis ongoing.

June 4 Immutep

Immutep reports positive interim Phase I data for IMP761

The single ascending dose Phase I met its primary endpoint, showing safety, tolerability and significant pharmacodynamic activity at 7 mg/kg; further updates expected in H2 2026.

Media coverage

July 24 Kalkine

Immutep's Eftilagimod Alfa Quality of Life Data Accepted for ESMO Congress 2026 Presentation

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a late-stage immunotherapy company, has announced that an abstract evaluating health-related quality of life outcomes from its investigator-initiated EFTISARC-NEO...

July 14 Markets Insider

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number...

July 12 The Courier-Mail

Health Check: Immutep shares bounce on revived lung cancer treatment hopes

Immutep (ASX:IMM) shares this morning have bounced a Lazarus-like 30% on a further update from the cell therapy drug developer about its lung cancer program.

June 30 The Globe and Mail

Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

June 29, 2026) - Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate On...

Never miss news about Immutep

Track Immutep and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Immutep competitors & trending companies

Browse news for competitors to Immutep and other trending companies.